Abstract | OBJECTIVE: T cell costimulation is a key point in the regulation of immune tolerance, immune response, and autoimmunity. T cell activation does not take place upon the simple engagement of T cell receptor; a second signal is needed to fully stimulate T cells. There are a variety of molecules that can act as costimulators, and among those CD28/CD80 signaling plays a crucial role in modulating T cell response. Cytotoxic T lymphocyte antigen-4, CD152 (CTLA4) is a physiologic antagonist of CD28, and abatacept, a synthetic analog of CTLA4, has recently been approved to treat rheumatoid arthritis. An abnormal T cell activation is also believed to sustain psoriatic disease both at skin and joint sites. We aimed to evaluate the rationale of blocking CD28/CD80 signaling and the possible use of abatacept for treating psoriatic arthritis (PsA). METHODS: We reviewed the role of CD28/CD80 signaling in promoting T cell inflammation in psoriasis and the effects of CTLA4 modulation in experimental models of psoriasis and in humans. RESULTS: CONCLUSION: Although the CD28 molecule is crucial in activating T cells and inflammation in psoriasis, data on the efficacy of abatacept in the treatment of PsA are still not conclusive.
|
Authors | Florenzo Iannone, Giovanni Lapadula |
Journal | The Journal of rheumatology. Supplement
(J Rheumatol Suppl)
Vol. 89
Pg. 100-2
(Jul 2012)
ISSN: 0380-0903 [Print] Canada |
PMID | 22751606
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Inflammatory Agents
- B7-1 Antigen
- CD28 Antigens
- Immunoconjugates
- Abatacept
|
Topics |
- Abatacept
- Animals
- Anti-Inflammatory Agents
(therapeutic use)
- Arthritis, Psoriatic
(drug therapy, immunology)
- B7-1 Antigen
(metabolism)
- CD28 Antigens
(metabolism)
- Humans
- Immunoconjugates
(therapeutic use)
- Lymphocyte Activation
(drug effects)
- Signal Transduction
(drug effects)
- T-Lymphocytes
(drug effects, immunology)
- Treatment Outcome
|